NASDAQ$VIR
Vir Biotechnology Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2021.
Vir Biotechnology reported total revenues of $812.7 million for the quarter ended December 31, 2021, primarily driven by collaboration revenue from sotrovimab sales. Net income for the quarter was $525.3 million, or $3.92 per share diluted.
- Significant progress made increasing global patient access to sotrovimab.
- Approximately 1.7 million doses of sotrovimab sold to date.
- $917.2 million of sotrovimab collaboration revenue recognized in 2021.
- Multiple commercial and clinical value drivers expected across the portfolio in 2022.
Headline financials
Revenue & EPS history
Vir · Revenue · Quarterly
$813M
Revenue by segment
Vir · $813M total across 2 segments · Q4 2021
- License & collaboration revenue$810M—99.6%
- Grant revenue$3M+109.4%0.4%
Forward guidance
Based solely on the binding agreements received to date, the Company expects to recognize approximately $1.1 billion of sotrovimab collaboration revenues when the doses are delivered in the first half of 2022.
Tailwinds
- Continue to advance its broad HBV portfolio aimed at the pursuit of a functional cure.
- Initial data from the first cohorts of Phase 2 MARCH trial of VIR-2218 in combination with VIR-3434, are expected in the first half of 2022.
- Additional data from the Phase 2 trial of VIR-2218 in combination with PEG-IFN-α are expected in the first half of 2022.
- Additional data from the Phase 1 monotherapy trial of VIR-3434 are expected in the first half of 2022.
- Additional data from the proof-of-concept Phase 1 trial of VIR-1111 are expected in the first half of 2022.
Headwinds
- Initial feedback from the FDA question Vir’s conclusion that the 500 mg IV dose of sotrovimab retains activity against the BA.2 Omicron subvariant based on Vir’s current modeling assumptions.
- The FDA has asked for additional data to support Vir’s position.
- The agency also requested safety data for higher doses.
- There are limited clinical data available for sotrovimab.
- Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+2.0%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
43%
12 / 28 earnings
Positive
+27.7%
Q4 2025
Best reaction
-15.1%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | -7.2% | -13.7% | |
| Q4 2025 | +27.7% | +22.3% | +20.6% | |
| Q3 2025 | -5.6% | -8.9% | +8.3% | |
| Q1 2025 | -3.4% | -16.2% | -2.9% | |
| Q4 2024 | -11.8% | -10.9% | -27.2% | |
| Q3 2024 | +21.8% | +26.8% | +4.7% | |
| Q2 2024 | -9.4% | -15.4% | -18.7% | |
| Q1 2024 | +18.9% | +13.6% | +17.5% | |
| Q4 2023 | +14.0% | +13.1% | -0.6% | |
| Q3 2023 | +12.5% | +8.3% | +24.4% | |
| Q2 2023 | -3.0% | -4.8% | -10.9% | |
| Q1 2023 | -3.5% | -4.5% | +7.5% | |
| Q4 2022 | -14.8% | -15.6% | -16.7% | |
| Q3 2022 | +15.0% | +20.3% | +23.7% | |
| Q2 2022 | +2.0% | -4.9% | -25.9% | |
| Q1 2022 | -3.1% | -1.4% | +12.5% | |
| Q4 2021 | +0.1% | -13.7% | -21.5% | |
| Q3 2021 | -15.1% | -11.7% | +20.4% | |
| Q2 2021 | +3.3% | +10.5% | +32.0% | |
| Q1 2021 | -1.0% | -8.5% | +3.5% | |
| Q4 2020 | -4.2% | -11.7% | -21.2% | |
| Q3 2020 | +8.2% | +5.8% | +26.0% | |
| Q2 2020 | -0.6% | -0.9% | -46.8% | |
| Q2 2019 | -0.6% | -0.9% | -46.8% | |
| Q1 2020 | -1.9% | -3.1% | +7.2% | |
| Q1 2019 | -1.9% | -3.1% | +7.2% | |
| Q4 2019 | +11.5% | +11.4% | +6.0% | |
| Q3 2019 | -3.0% | -0.5% | -3.7% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro